7 studies digested so far, newest first. The BPC-157 profile summarizes the evidence and lists the studies it was written from.
A narrative review in The Journal of the American Academy of Orthopaedic Surgeons searched three databases through June 2026 and reports that direct musculoskeletal evidence for BPC-157 is predominantly small-animal work, with human data limited to one uncontrolled case series.
A narrative review in Pharmaceuticals surveys cytoprotective approaches to liver injury, comparing BPC 157 with agents such as N-acetylcysteine and melatonin, and states that experimental evidence does not establish clinical efficacy.
A narrative review of regenerative peptides including BPC-157 presents three uncontrolled clinical cases of inferior alveolar nerve injury managed with peptides, dexamethasone and local anesthetic; the authors report neurosensory recovery but state causality cannot be established.
A PRISMA-compliant systematic review identified three human studies of BPC-157 totalling 30 participants. All reported symptom improvement without treatment-related adverse events, but were judged poor quality with very low certainty of evidence.
A narrative review in Missouri Medicine groups BPC-157 with TB-500, melanotan-II and other non-prescription injectables, stating these substances lack established human safety profiles and outlining categories of potential toxicity.
A ClinicalTrials.gov registration outlines a randomized, double-blind, placebo-controlled pilot trial of daily subcutaneous BPC-157 for 90 days after arthroscopic rotator cuff repair in twenty patients. No results are reported.
A review of rodent ischemia-reperfusion injury models summarizes reported effects of BPC 157 on oxidative, inflammatory and vascular markers, with no meta-analysis performed because of heterogeneity.